Pharmacoeconomic analysis of biological disease modifying antirheumatic drugs in patients with rheumatoid arthritis based on real-world data from the IORRA observational cohort study in Japan

Tanaka, Eiichi; Inoue, Eisuke; Yamaguchi, Rei; Shimizu, Yoko; Kobayashi, Akiko; Sugimoto, Naoki; Hoshi, Daisuke; Shidara, Kumi; Sato, Eri; Seto, Yohei; Nakajima, Ayako; Momohara, Shigeki; Taniguchi, Atsuo; Yamanaka, Hisashi

doi:10.1080/14397595.2016.1205799

Cited by 14 publications

(10 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Researchers have been able to apply simulation analysis to the IORRA cohort, accessing routine treatment data from Japanese patients with RA. With this approach, we showed it is economically feasible to use bDMARDs for treating patients with RA who have high disease activity [17].…”

Section: Pharmacoeconomics Of Ra Therapymentioning

confidence: 99%

A large observational cohort study of rheumatoid arthritis, IORRA: Providing context for today’s treatment options

Yamanaka

Tanaka

Nakajima

et al. 2019

Modern Rheumatology

Self Cite

View full text Add to dashboard Cite

Real-world evidence, based on real-world data from routine clinical treatment, is becoming increasingly important for providing high-quality medical care. Large-scale cohort studies can provide useful access to some of this real-world evidence, as shown by the IORRA (Institute of Rheumatology, Rheumatoid Arthritis) cohort in Japan. This large cohort study of patients with rheumatoid arthritis (RA) has been surveying enrolled participants since its inception in 2000. In the last 19 years, it has served as a database for a wide range of research in areas including transitions in medical care at the clinical level, changes in therapeutic drugs, approaches to comorbidities, developments in pharmacoeconomics, and the effects of genomic information on treatment options. This research has resulted in the publication of 133 articles in English to date. IORRA monitors changes in the management of RA, and has quantified over time the daily experience of clinicians who provide routine medical care. Such observational databases, which reflect the reality of daily clinical practice, will become increasingly important and may provide a model for similar research in other disease areas. ARTICLE HISTORY

show abstract

Section: Pharmacoeconomics Of Ra Therapymentioning

confidence: 99%

A large observational cohort study of rheumatoid arthritis, IORRA: Providing context for today’s treatment options

Yamanaka

Tanaka

Nakajima

et al. 2019

Modern Rheumatology

Self Cite

View full text Add to dashboard Cite

show abstract

“…When using society as a research perspective of cost, opportunity cost instead of acquisition cost should be measured as the cost of interventions or programs. However, in all the studies that we included using society as the perspective, the costs were directly used acquisition costs, and there was no discussion why these costs were not adjusted into opportunity costs ( Lindgren et al, 2009 ; Lekander et al, 2010 ; Yang et al, 2010 ; Lekander et al, 2013 ; Aarnio et al, 2015 ; Zhao et al, 2016 ; Tanaka et al, 2017 ; Vassall et al, 2017 ; Dor et al, 2018 ; de Jong et al, 2019a ; de Jong et al, 2019b ; Behan et al, 2019 ; Lin et al, 2019 ; Voermans et al, 2019 ; Wang et al, 2019 ; Arrobas et al, 2021 ). This might lead to the overestimation of costs and ICER.…”

Section: Discussionmentioning

confidence: 99%

Big Data and Real-World Data based Cost-Effectiveness Studies and Decision-making Models: A Systematic Review and Analysis

Xiong

Lee

et al. 2021

Front. Pharmacol.

View full text Add to dashboard Cite

Background: Big data and real-world data (RWD) have been increasingly used to measure the effectiveness and costs in cost-effectiveness analysis (CEA). However, the characteristics and methodologies of CEA based on big data and RWD remain unknown. The objectives of this study were to review the characteristics and methodologies of the CEA studies based on big data and RWD and to compare the characteristics and methodologies between the CEA studies with or without decision-analytic models. Methods: The literature search was conducted in Medline (Pubmed), Embase, Web of Science, and Cochrane Library (as of June 2020). Full CEA studies with an incremental analysis that used big data and RWD for both effectiveness and costs written in English were included. There were no restrictions regarding publication date. Results: 70 studies on CEA using RWD (37 with decision-analytic models and 33 without) were included. The majority of the studies were published between 2011 and 2020, and the number of CEA based on RWD has been increasing over the years. Few CEA studies used big data. Pharmacological interventions were the most frequently studied intervention, and they were more frequently evaluated by the studies without decision-analytic models, while those with the model focused on treatment regimen. Compared to CEA studies using decision-analytic models, both effectiveness and costs of those using the model were more likely to be obtained from literature review. All the studies using decision-analytic models included sensitivity analyses, while four studies no using the model neither used sensitivity analysis nor controlled for confounders. Conclusion: The review shows that RWD has been increasingly applied in conducting the cost-effectiveness analysis. However, few CEA studies are based on big data. In future CEA studies using big data and RWD, it is encouraged to control confounders and to discount in long-term research when decision-analytic models are not used.

show abstract

“…A detailed analysis of the health economic effects of anti‐mAb drugs for treating rheumatoid arthritis has been previously carried out in Japan 2 . However, there is a paucity of data on the health economic benefits with respect to multiple sclerosis (MS) and neuromyelitis optica spectrum disorders (NMOSD).…”

Section: Introductionmentioning

confidence: 99%

The impact of monoclonal antibody drugs on healthcare economics in the treatment of multiple sclerosis and neuromyelitis optica spectrum disorders

Ohashi

2022

Clinical & Exp Neuroim

View full text Add to dashboard Cite

The launch of highly efficacious anti‐monoclonal antibody (mAb) drugs has profoundly changed the therapeutic strategy for multiple sclerosis and neuromyelitis optica spectrum disorders (NMOSD). However, the newly developed anti‐mAb drugs, especially those used in treating NMOSD, are quite expensive, resulting in a significant medical and economic burden. Early use of these drugs is expected to reduce the frequency of relapse and the accumulation of disability, preserve the quality of life of patients, and improve their life expectancy. In selecting therapeutic drugs, it is necessary not only to consider the efficacy and safety of the drugs, but also to consider the cost‐effectiveness of each drug for each patient, considering the economic aspects of health care. However, the cost‐effectiveness of anti‐mAb drugs in treating multiple sclerosis and NMOSD has not been fully verified. Japan is rapidly emerging as a hyper‐aged society, unlike any other in the world, and the rising cost of medical care is an urgent issue that needs to be addressed and resolved. Out‐of‐pocket expenses of individual patients are not a major issue in Japan as medical, costs for multiple sclerosis and NMOSD are subsidized by public medical insurance; however, the judicious use of anti‐mAb drugs is required to ensure cost‐effectiveness.

show abstract

Pharmacoeconomic analysis of biological disease modifying antirheumatic drugs in patients with rheumatoid arthritis based on real-world data from the IORRA observational cohort study in Japan

Abstract: bDMARDs were cost-effective for RA patients based on a real-world setting in Japan.

Cited by 14 publications

References 21 publications

A large observational cohort study of rheumatoid arthritis, IORRA: Providing context for today’s treatment options

A large observational cohort study of rheumatoid arthritis, IORRA: Providing context for today’s treatment options

Big Data and Real-World Data based Cost-Effectiveness Studies and Decision-making Models: A Systematic Review and Analysis

The impact of monoclonal antibody drugs on healthcare economics in the treatment of multiple sclerosis and neuromyelitis optica spectrum disorders

Contact Info

Product

Resources

About